We provide you with 20 years of free, institutional-grade data for PRAX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PRAX. Explore the full financial landscape of PRAX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| MITCHELL DEAN J | Derivatives Exercise | 12,251 | 2025-09-25 | ||
| Kelly Timothy Edwin | Grant, award...etc | 249 | $31.54 | 2025-05-19 | |
| Souza Marcio | Grant, award...etc | 348 | $31.54 | 2025-05-19 | |
| Mastrocola Lauren | Sale | -40 | $85.4 | $3,416 | 2025-02-14 |
| Nemiroff Alex | Sale | -51 | $85.4 | $4,355 | 2025-02-14 |
| Souza Marcio | Sale | -401 | $85.4 | $34,245 | 2025-02-14 |
| Nemiroff Alex | Sale | -579 | $63.15 | $36,564 | 2025-01-14 |
| Nemiroff Alex | Grant, award...etc | 11,250 | 2025-01-14 | ||
| Souza Marcio | Grant, award...etc | 37,500 | 2025-01-14 | ||
| Mastrocola Lauren | Sale | -390 | $63.15 | $24,629 | 2025-01-14 |
| Mastrocola Lauren | Grant, award...etc | 5,000 | 2025-01-14 | ||
| Kelly Timothy Edwin | Sale | -676 | $63.15 | $42,689 | 2025-01-14 |
| Kelly Timothy Edwin | Grant, award...etc | 12,500 | 2025-01-14 | ||
| Nemiroff Alex | Sale | -89 | $77.52 | $6,899 | 2025-01-08 |
| Souza Marcio | Sale | -434 | $77.52 | $33,644 | 2025-01-08 |
| Kelly Timothy Edwin | Sale | -139 | $77.52 | $10,775 | 2025-01-08 |
| Mastrocola Lauren | Sale | -35 | $77.52 | $2,713 | 2025-01-08 |
| Mastrocola Lauren | Grant, award...etc | 294 | $37.4 | 2024-11-19 | |
| Kelly Timothy Edwin | Grant, award...etc | 205 | $37.4 | 2024-11-19 | |
| Nemiroff Alex | Sale | -8,239 | $80.2 | $660,801 | 2024-11-15 |
| Nemiroff Alex | Derivatives Exercise | 7,583 | 2024-11-15 | ||
| Mastrocola Lauren | Sale | -5,188 | $81.78 | $424,290 | 2024-11-15 |
| Mastrocola Lauren | Derivatives Exercise | 4,374 | 2024-11-15 | ||
| Mastrocola Lauren | Grant, award...etc | 4,500 | 2024-07-31 | ||
| Kelly Timothy Edwin | Grant, award...etc | 7,800 | 2024-07-31 | ||
| Nemiroff Alex | Grant, award...etc | 7,800 | 2024-07-31 | ||
| Souza Marcio | Grant, award...etc | 1,718 | $12.37 | 2024-05-20 | |
| Kelly Timothy Edwin | Grant, award...etc | 606 | $12.37 | 2024-05-20 | |
| Souza Marcio | Sale | -271 | $44.65 | $12,100 | 2024-02-14 |
| Nemiroff Alex | Sale | -51 | $44.65 | $2,277 | 2024-02-14 |
| Mastrocola Lauren | Sale | -48 | $44.65 | $2,143 | 2024-02-14 |
| Nemiroff Alex | Sale | -89 | $25.19 | $2,242 | 2024-01-09 |
| Kelly Timothy Edwin | Sale | -139 | $25.19 | $3,501 | 2024-01-09 |
| Souza Marcio | Sale | -418 | $25.19 | $10,529 | 2024-01-09 |
| Mastrocola Lauren | Sale | -35 | $25.19 | $882 | 2024-01-09 |
| DeSimone Jill | Open Market Purchase | 14,500 | $1.75 | 2023-10-10 | |
| Souza Marcio | Open Market Purchase | 10,000 | $1.06 | 2023-06-27 | |
| Kelly Timothy Edwin | Grant, award...etc | 11,683 | $0.88 | 2023-05-18 | |
| Nemiroff Alex | Grant, award...etc | 11,686 | $0.88 | 2023-05-18 | |
| Souza Marcio | Grant, award...etc | 11,687 | $0.88 | 2023-05-18 | |
| Kelly Timothy Edwin | Open Market Purchase | 8,000 | $0.87 | 2023-04-06 | |
| Souza Marcio | Open Market Purchase | 35,001 | $0.86 | 2023-03-27 | |
| Souza Marcio | Open Market Purchase | 35,000 | $0.86 | 2023-03-27 | |
| MITCHELL DEAN J | Open Market Purchase | 50,000 | $0.84 | 2023-03-27 | |
| Kelly Timothy Edwin | Open Market Purchase | -8,000 | $0.87 | $6,998 | 2023-03-27 |
The information provided in this report about PRAX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Praxis Precision Medicines, Inc(NASDAQ:PRAX) 
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in...
Website: http://www.praxismedicines.com
Founded: 2015
Full Time Employees: 50
CEO: Marcio Souza
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends